Download PDFPDF
Circulating microrna as novel early biomarker of concussion in elite athletes
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Update on Fluid-Based Biomarkers in Sports-Related Concussion Diagnosis
    • Matthew J Rogatzki, Assistant professor Appalachian State University, Boone, NC, USA
    • Other Contributors:
      • Gareth Irwin, Professor and Head of Sports Biomechanics
      • Geneieve KR Williams, Lecturer
      • Jiao Jiao, Post-doctoral Research Fellow
      • Wei Liang, Post-doctoral Research Fellow
      • Binh Quach, Technical Director
      • Rongjun Yu, Associate Professor
      • Huw Wiltshire, Principal Lecturer and and Associate Dean of Enterprise in the Cardiff School of Sport
      • Julien S. Baker, Head and Professor, Director, Centre for Health and Exercise Science Research


    Recently, an article by Di Pietro and colleagues investigating small non-coding RNAs (sncRNA)s in the saliva of concussed rugby players was published in the British Journal of Sports Medicine (BJSM), a highly rated sports medicine journal [1]. Due to the groundbreaking nature of the study, many media outlets published articles celebrating the authors’ findings. One such article from the Washington Post was titled: “Concussions can be diagnosed through a saliva test, British researchers find.”[2]. As a result, colleagues and clinicians have contacted members of the Sport and Health Interdisciplinary group in Movement & Performance from Acute & Chronic head Trauma (IMPACT), a recently formed international group investigating concussion injury, asking our opinion of the article and what the findings mean for sports-related concussion (SRC) diagnosis. Similar questions emerged in 2018 when the United States of America Food and Drug Administration (FDA) announced approval of a blood test using glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal esterase L1 (UCHL1) to differentiate between computed tomography (CT)-positive and CT-negative results. The headline for this announcement read: “FDA authorizes marketing of first blood test to aid in the evaluation of concussion in adults,”[3] which led to confusion among clinicians as to what this meant for concussion assessment and diagnosis. Therefore, the interdisciplinary IMPACT team t...

    Show More
    Conflict of Interest:
    None declared.